Department of Surgery, Division of Vascular Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL; Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Northwestern Medicine, Chicago, IL.
Department of Surgery, Division of Vascular Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL.
Ann Vasc Surg. 2022 Nov;87:205-212. doi: 10.1016/j.avsg.2022.06.004. Epub 2022 Jul 12.
Ischemic stroke is a devastating complication of thoracic endovascular aortic repair (TEVAR). This risk may be higher in more proximal aneurysms that require arch manipulation. The purpose of this study is to (1) describe 30-day stroke and death rates in patients undergoing TEVAR, (2) compare stroke rates in patients undergoing TEVAR for arch versus descending aneurysm pathology, and (3) identify predictive factors associated with stroke after TEVAR.
The Vascular Quality Initiative registry was queried (2015-2021) for TEVAR procedures performed for degenerative aneurysms. Our primary outcomes were any stroke or death at 30 days. Patient-, procedure-, and hospital-level predictors of stroke were assessed using multivariable Poisson regression.
Among 3,072 patients with degenerative aneurysms (197 [6.4%] arch versus 2,875 [93.6%] descending) treated with elective TEVAR, the median age was 73 years (interquartile range 67-79) and 54.8% were male. Within the arch aneurysm group, there were 27.4% zone 0, 22.8% zone 1, and 49.8% zone 2 interventions. Overall 30-day stroke and death rates were 3.2% and 3.8%. The distribution of stroke events was bilateral (52.9%), left carotid (20.7%), left vertebrobasilar (11.5%), right carotid (9.2%), and right vertebrobasilar (5.7%). Although mortality was similar between groups, the rate of ischemic stroke was higher for patients undergoing TEVAR for arch aneurysm versus descending aneurysms (7.1% arch versus 2.9% descending, P = 0.001). Factors that were associated with ischemic stroke after TEVAR included age (>79 years, relative risk [RR] 1.79, 95% confidence interval [CI] 1.08-2.98 vs. <79 years), dependent functional status (RR 1.73, 95% CI 1.07-2.78), procedural time (RR 1.25, 95% CI 1.15-1.36), and endovascular intervention for supra-aortic trunk revascularization (RR 2.66, 95% CI 1.06-6.70 versus no intervention).
Ischemic stroke risk after TEVAR was increased for arch aneurysms compared to descending aneurysms. More proximal zone coverage and endovascular interventions on the supra-aortic trunks were associated with increasing risk for stroke. Adequate preparation for stroke prevention is necessary prior to TEVAR with supra-aortic trunk revascularization.
胸主动脉腔内修复术(TEVAR)后发生缺血性卒中是一种严重的并发症。需要进行弓部操作的更靠近近端的动脉瘤发生这种风险的可能性更高。本研究的目的是:(1)描述接受 TEVAR 治疗的患者的 30 天卒中发生率和死亡率;(2)比较接受 TEVAR 治疗的弓部与降部动脉瘤患者的卒中发生率;(3)确定与 TEVAR 后卒中相关的预测因素。
对 2015 年至 2021 年血管质量倡议登记处(Vascular Quality Initiative registry)中接受退行性动脉瘤 TEVAR 治疗的患者进行了查询。我们的主要结局是 30 天内任何卒中或死亡。使用多变量泊松回归评估患者、手术和医院水平的卒中预测因素。
在 3072 例接受退行性动脉瘤(197 例[6.4%]为弓部,2875 例[93.6%]为降部)择期 TEVAR 治疗的患者中,中位年龄为 73 岁(四分位距 67-79),54.8%为男性。在弓部动脉瘤组中,0 区占 27.4%,1 区占 22.8%,2 区占 49.8%。总体而言,30 天卒中发生率和死亡率分别为 3.2%和 3.8%。卒中事件的分布为双侧(52.9%)、左侧颈动脉(20.7%)、左侧椎基底动脉(11.5%)、右侧颈动脉(9.2%)和右侧椎基底动脉(5.7%)。尽管两组死亡率相似,但接受 TEVAR 治疗的弓部动脉瘤患者的缺血性卒中发生率高于降部动脉瘤患者(7.1%的弓部 versus 2.9%的降部,P=0.001)。TEVAR 后发生缺血性卒中的相关因素包括年龄(>79 岁,相对风险 [RR] 1.79,95%置信区间 [CI] 1.08-2.98 与<79 岁,RR 1.73,95% CI 1.07-2.78)、依赖性功能状态、手术时间(RR 1.25,95% CI 1.15-1.36)和主动脉弓上干血运重建的血管内介入(RR 2.66,95% CI 1.06-6.70 与无干预,RR 1.73,95% CI 1.07-2.78)。
与降部动脉瘤相比,TEVAR 后弓部动脉瘤的缺血性卒中风险增加。更靠近近端的区域覆盖和主动脉弓上干的血管内干预与卒中风险的增加相关。在进行主动脉弓上干血运重建的 TEVAR 之前,需要充分准备预防卒中。